Order Article Reprints

Salvanou E-A, Kolokithas-Ntoukas A, Prokopiou D, Theodosiou M, Efthimiadou E, Koźmiński P, Xanthopoulos S, Avgoustakis K, Bouziotis P. ¹⁷⁷Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer. Molecules. 2024; 29(5):1030. https://doi.org/10.3390/molecules29051030

Salvanou, Evangelia-Alexandra, Argiris Kolokithas-Ntoukas, Danai Prokopiou, Maria Theodosiou, Eleni Efthimiadou, Przemysław Koźmiński, Stavros Xanthopoulos, Konstantinos Avgoustakis, and Penelope Bouziotis. 2024. "¹⁷⁷Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer" Molecules 29, no. 5: 1030. https://doi.org/10.3390/molecules29051030

Salvanou, E.-A., Kolokithas-Ntoukas, A., Prokopiou, D., Theodosiou, M., Efthimiadou, E., Koźmiński, P., Xanthopoulos, S., Avgoustakis, K., & Bouziotis, P. (2024). ¹⁷⁷Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer. Molecules, 29(5), 1030. https://doi.org/10.3390/molecules29051030